Free Trial
NYSE:MTNB

Matinas Biopharma (MTNB) Stock Price, News & Analysis

Matinas Biopharma logo
$0.93 -0.03 (-3.13%)
Closing price 08/5/2025 04:00 PM Eastern
Extended Trading
$1.08 +0.15 (+16.13%)
As of 04:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Matinas Biopharma Stock (NYSE:MTNB)

Key Stats

Today's Range
$0.87
$0.96
50-Day Range
$0.81
$1.04
52-Week Range
$0.47
$8.39
Volume
79,406 shs
Average Volume
299,486 shs
Market Capitalization
$4.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Matinas Biopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
12th Percentile Overall Score

MTNB MarketRank™: 

Matinas Biopharma scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Matinas Biopharma is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Matinas Biopharma is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Matinas Biopharma has a P/B Ratio of 0.21. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.82% of the float of Matinas Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Matinas Biopharma has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Matinas Biopharma has recently decreased by 41.81%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Matinas Biopharma does not currently pay a dividend.

  • Dividend Growth

    Matinas Biopharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.82% of the float of Matinas Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Matinas Biopharma has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Matinas Biopharma has recently decreased by 41.81%, indicating that investor sentiment is improving significantly.
  • MarketBeat Follows

    2 people have added Matinas Biopharma to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Matinas Biopharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.60% of the stock of Matinas Biopharma is held by insiders.

  • Percentage Held by Institutions

    Only 11.77% of the stock of Matinas Biopharma is held by institutions.

  • Read more about Matinas Biopharma's insider trading history.
Receive MTNB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Matinas Biopharma and its competitors with MarketBeat's FREE daily newsletter.

MTNB Stock News Headlines

MTNB Matinas BioPharma Holdings, Inc. - Seeking Alpha
Matinas BioPharma Holdings, Inc. (MTNB) - Yahoo Finance
HIDDEN IN THE BOOK OF GENESIS…
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.
Matinas BioPharma files to sell 16.9M shares of common stock for holders
Matinas BioPharma appoints Murphy, Neugeboren to board of directors
See More Headlines

MTNB Stock Analysis - Frequently Asked Questions

Matinas Biopharma's stock was trading at $0.51 at the start of the year. Since then, MTNB stock has increased by 82.4% and is now trading at $0.93.

Matinas Biopharma Holdings, Inc. (NYSE:MTNB) issued its earnings results on Wednesday, August, 14th. The company reported ($0.02) EPS for the quarter, meeting analysts' consensus estimates of ($0.02).

Shares of MTNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Matinas Biopharma investors own include AcelRx Pharmaceuticals (ACRX), DURECT (DRRX), Kosmos Energy (KOS), Strongbridge Biopharma (SBBP), Selecta Biosciences (SELB), Acasti Pharma (ACST) and Abeona Therapeutics (ABEO).

Company Calendar

Last Earnings
8/14/2024
Today
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:MTNB
Previous Symbol
NYSE:MTNB
CIK
1582554
Web
N/A
Fax
N/A
Employees
30
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($3.86)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$22.94 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-123.06%
Return on Assets
-94.28%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.53
Quick Ratio
5.53

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.43 per share
Price / Book
0.21

Miscellaneous

Outstanding Shares
5,087,000
Free Float
4,599,000
Market Cap
$4.73 million
Optionable
N/A
Beta
1.32

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NYSE:MTNB) was last updated on 8/6/2025 by MarketBeat.com Staff
From Our Partners